With Gilead’s Lock In Hepatitis C, What’s Next For The Field?

The competition in HCV is virtually concluded, as Gilead exited the AASLD conference holding a best-in-class advantage in terms of efficacy and convenience. Its hold on the market may prove impregnable for other comers, but as Yogi Berra said, “It ain’t over till it’s over.”